Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

y's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird,

Director of Public Relations

PAREXEL International

Tel: +781-434-4409

Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo

SHIFT Communications

Tel : +617-779-1817

Email : rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...mab Program to be Discontinued and Headcount to be... its Portfolio Review; Zanolimumab Program to be ...r of Employees, COP...b A/S (OMX: GEN),announced today that it is discon... In addition, as a result of a portfolio review an...
(Date:10/8/2008)...gs Confirm Potency of Poly-ICR as Vaccine Adjuvant...nta Biopharmaceuticals,Corporation (TSX: NVN) toda... using its proprietary Toll-like Receptor 3 agonis...Vaccine Congress 2008 in Lyon, France.,Study resul...juvant,targeting the Toll-like Receptor 3 (TLR3) p...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
(Date:10/7/2008)...s, Oct. 7 /- The Texas Cardiac Arrhyt...r has been selected as one of,only a few sites in ...cal,trial for a new device to treat persistent atr..., training and research center specializing in hea...David,s Medical Center and,Texas Cardiovascular Co...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Park Dental Announces Separation From Its Administrative Service Provider 13335 1Park Dental Announces Separation From Its Administrative Service Provider 13335 2Park Dental Announces Separation From Its Administrative Service Provider 13335 3Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 1Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 1Pump It Up and Autism Society of America Launch Bounce for Autism 13331 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 3MSU research indicates testosterone could guard against eating disorders 13329 1MSU research indicates testosterone could guard against eating disorders 13329 2
...the CDC that none of its influenza vaccine (Fluvir...ted States for the current influenza season. In th...e anticipated American vaccine supply, medical off...gly alarmed about the scarcity of vaccine and the ...e seen if virulent new strains of flu or an abnorm...
...f rapid, easy-to-use diagnostic tests, many assays...ace to help clinicians assess dosage appropriatene...ence of drugs of abuse. Some of these products req...s are suitable for point of care use by medical pr..., Therapeutic drug monitoring measures the serum ...
Other Medicine Technology:Rapid Flu Tests May Prove Especially Helpful This Season 2Rapid Flu Tests May Prove Especially Helpful This Season 3Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 2Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 3Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 4
(Date:10/10/2008)...t. 10 /PRNewswire/ -- A nationally recognized facu...ies for patients with breast,cancer in the multime...tegies: From Biomarkers to Treatment Selection" du...is challenging for practicing oncologists and othe...ate on the latest patient care,advances. This accr...
(Date:10/9/2008)...ACH, Fla., Oct. 9 /PRNewswire/ -- This may sound l...reality. Internationally,acclaimed anti-aging Doct...licensed to provide TA-65 to the public through hi...ida., This is a revolutionary technology that is ...our DNA. They are located at the ends of all the,c...
(Date:10/9/2008)...y Rewards and Educational Opportunities for Those ...PHILADELPHIA, Oct. 9 /PRNewswire/ -- In recognitio...Blue Cross (IBC) honors its more than,590 customer... with fun,healthy activities this week and celebr...., Fielding more than 4 million inquiries a year,...
(Date:10/9/2008)...s., Oct. 9 /PRNewswire/ -- Nature,s Way Holding Co...hwabe Pharmaceuticals, a leading,worldwide produce...,agreement to acquire all outstanding shares of En...he controlling shareholder of Enzymatic Therapy. T...vering their signatures and,provides for customary...
Breaking Medicine News(10 mins):Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2Health News:Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging 2Health News:Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging 3Health News:Independence Blue Cross Celebrates Customer Service Week 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 3
...se or survival for children and young adults with ...ancer Hospital at The University of Texas M. D. A...g leukemia patients over the past decade has shown...C), a measure of normal immune cells found on ever...
...boosted the potency of platinum-based cancer drugs... cell lines and to mice with tumors, scientists f...g a platinum chemotherapy agent and the diabetes d...e tumors as much as three times more effectively t...
...ect for countries that recently have made progress...t released on Monday by Save the Children, the Ne... the World's Mothers: Saving the Lives of Children... a mother and child in 60 developing countries whe...
...urnal of the American Medical Association, researc...of contracting lymphoma. The cancer of the immun...d to be 30 percent times higher in patients with h...denstroms macroglobulinemia, the risk of a hepatit...
Other Medicine News:Health News:Lymphocyte Count Found to Be a Predictor of Survival for Young Patients With Leukemia 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 3Health News:Family Planning Initiatives Central To Reducing Child Mortality in Developing Countries 2Health News:Hepatitis C Carries Another Risk-Cancer Of The Immune System 2
...medication, food, exercise, stress . . . Theyre al...health. Unfortunately, its difficult, and often ov...tion on a daily basis. Its even more difficult to ...formation to a care provider quickly so healthcare...
...es requires making decisions about insulin dosages... These decisions are guided by data from blood glu...the patterns that can be seen by you and your Heal...ganized and graphical formats. The FreeStyle CoPil...
...t Solid-State Three-Color Photocoagulator.,Retin...purchase over 3,000 Lumenis multi-color photocoagu...ractice, the Novus Varia integrates green, yellow,... single, compact system that supports your treatme...
...pe 14, 14A and 14C have been approved. The three r...modate the variations in the size of the individua... rings are designed to stabilize the capsule and h...e panel of U.S. ophthalmologists. For implatation...
Medicine Products: